Kala Pharmaceuticals, Inc. (KALA) Ownership
KALA ownership summary
as of October 18, 2026- Institutions
- 4.1% of shares outstanding
- Insiders
- 1.24% of shares outstanding
- Shares outstanding
- 19.3M
- Float
- 19.3M shares available to trade
- Short interest
- 7.06% 1.4M shares short
- Days to cover
- 0.37 short interest up 205.1% vs prior month
- Institutions 4.07%
- Insiders 1.24%
- Other investors 94.69%
KALA top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management, LLC | 1.14% | 221K | $41,896 | +219,412 (+18,118.2%) | June 30, 2026 |
| 2 | Geode Capital Management, LLC | 0.75% | 145K | $27,564 | +139,931 (+2,680.2%) | June 30, 2026 |
| 3 | Vanguard Fiduciary Trust Co | 0.52% | 101K | $19,255 | +100,803 (+16,998.8%) | June 30, 2026 |
| 4 | State Street Corp | 0.46% | 89K | $16,819 | +87,998 (+15,384.3%) | June 30, 2026 |
| 5 | BlackRock Inc | 0.37% | 72K | $13,586 | +71,326 (+33,021.3%) | June 30, 2026 |
| 6 | Northern Trust Corp | 0.22% | 42K | $7,901 | +41,376 (+17,989.6%) | June 30, 2026 |
| 7 | Qube Research & Technologies | 0.06% | 11K | $2,103 | +11,073 (0.0%) | June 30, 2026 |
| 8 | The Goldman Sachs Group Inc | 0.06% | 11K | $2,074 | +10,640 (+3,786.5%) | June 30, 2026 |
| 9 | UBS Group AG | 0.05% | 9,057 | $1,720 | +7,720 (+577.4%) | June 30, 2026 |
| 10 | Covestor Ltd | <0.01% | 1,264 | $240 | +1,264 (0.0%) | March 31, 2026 |
| 11 | Tower Research Capital LLC | <0.01% | 616 | $117 | +616 (0.0%) | June 30, 2026 |
| 12 | Barclays PLC | <0.01% | 608 | $115 | +608 (0.0%) | June 30, 2026 |
| 13 | Morgan Stanley - Brokerage Accounts | <0.01% | 28 | $5 | −31 (−52.5%) | June 30, 2026 |
| 14 | Caitong International Asset Management Co., Limited. | <0.01% | 10 | $2 | +10 (0.0%) | June 30, 2026 |
| 15 | International Assets Investment Management, LLC | 0.00% | 2 | $0 | — | June 30, 2026 |
| 16 | Jane Street Group LLC | 0.00% | — | — | −720 (−100.0%) | June 30, 2026 |
| 17 | SG Americas Securities, LLC | 0.00% | — | — | −10,359 (−100.0%) | March 31, 2026 |
| 18 | Steward Partners Investment Advisory, LLC | 0.00% | — | — | −2 (−100.0%) | June 30, 2026 |
| 19 | Citadel Advisors Llc | 0.00% | — | — | −5,633 (−100.0%) | June 30, 2026 |
| 20 | Woodline Partners LP | 0.00% | — | — | −224,174 (−100.0%) | March 31, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 693K shares and 6 cut 241K.
KALA top mutual fund and ETF holders
4 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Extended Market Index | 0.50% | 96K | $18,226 | −516 (−0.5%) | August 31, 2026 |
| 2 | Fidelity Series Total Market Index | 0.13% | 25K | $4,840 | +8,091 (+46.5%) | August 31, 2026 |
| 3 | Fidelity Total Market Index | 0.12% | 23K | $4,424 | +4,098 (+21.3%) | August 31, 2026 |
| 4 | Fidelity Nasdaq Composite Index | 0.07% | 13K | $2,437 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
KALA insider transactions
latest 17| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-23 | Mary Reumuth | Sell | $0.82 | 967 | $793 |
| 2025-10-23 | Mark T Iwicki | Sell | $0.81 | 154,894 | $125,464 |
| 2025-10-22 | Darius Kharabi | Sell | $0.83 | 20,806 | $17,269 |
| 2025-10-22 | Mary Reumuth | Sell | $0.83 | 32,230 | $26,751 |
| 2025-10-22 | Romulus K Brazzell | Sell | $0.83 | 46,748 | $38,801 |
| 2025-10-22 | Todd Bazemore | Sell | $0.83 | 47,768 | $39,647 |
| 2025-10-01 | Bros. Advisors Lp Baker | Sell | $1.38 | 513,607 | $708,778 |
| 2025-09-30 | Bros. Advisors Lp Baker | Sell | $1.60 | 216,801 | $346,882 |
| 2025-06-24 | Darius Kharabi | Sell | $4.01 | 4,511 | $18,089 |
| 2025-06-24 | Todd Bazemore | Sell | $4.01 | 4,058 | $16,273 |
| 2025-06-24 | Romulus K Brazzell | Sell | $4.01 | 5,251 | $21,057 |
| 2025-06-24 | Mary Reumuth | Sell | $4.01 | 3,631 | $14,560 |
| 2025-06-24 | Mark T Iwicki | Sell | $4.01 | 13,227 | $53,040 |
| 2025-06-03 | Darius Kharabi | Sell | $3.74 | 730 | $2,730 |
| 2025-06-03 | Mary Reumuth | Sell | $3.74 | 2,850 | $10,659 |
| 2025-06-03 | Romulus K Brazzell | Sell | $3.74 | 3,687 | $13,789 |
| 2025-06-03 | Todd Bazemore | Sell | $3.74 | 3,390 | $12,679 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
KALA shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns KALA
Institutional investors own 4.1% of Kala Pharmaceuticals's shares and insiders 1.24%. The largest holder is Vanguard Capital Management, LLC with 1.14% of the shares (221K), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 6 reduced their stake in the latest filings. Short interest is 7.06% of the float, or 0.37 days of average trading volume. The share count rose 15.2% since 2015.
Related: KALA analyst forecast, KALA key metrics. See the KALA stock overview for the latest quote and news.
KALA ownership FAQ
Who owns the most Kala Pharmaceuticals stock?
The largest shareholders of Kala Pharmaceuticals are Vanguard Capital Management, LLC (1.14%), Geode Capital Management, LLC (0.75%), Vanguard Fiduciary Trust Co (0.52%), State Street Corp (0.46%), BlackRock Inc (0.37%).
What percentage of Kala Pharmaceuticals is owned by institutions?
Institutions hold 4.1% of Kala Pharmaceuticals's shares outstanding; insiders hold 1.24%.
Which funds own Kala Pharmaceuticals?
The largest fund holders of Kala Pharmaceuticals are Fidelity Extended Market Index (0.50%), Fidelity Series Total Market Index (0.13%), Fidelity Total Market Index (0.12%), Fidelity Nasdaq Composite Index (0.07%).
What is Kala Pharmaceuticals's short interest?
1.4M shares of Kala Pharmaceuticals were sold short, 7.06% of the float; at the average daily volume it would take 0.37 days to cover.
Are insiders buying or selling Kala Pharmaceuticals?
Of the latest 17 reported insider transactions in Kala Pharmaceuticals (since June 3, 2025), 0 were purchases and 17 were sales.
How many shares of Kala Pharmaceuticals are outstanding?
Kala Pharmaceuticals has 19.3M shares outstanding, of which 19.3M are in the public float.